Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19

We report on a patient with refractory Myasthenia gravis with acetylcholine receptor antibodies with two prior myasthenic crises suffering from COVID-19 with rapid evolving weakness and respiratory failure. Respiratory failure developed and prolonged mechanical ventilation was necessary. After plasm...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofstadt-van Oy, Ulrich, Stankovic, Slobodan, Kelbel, Corinna, Oswald, Daniel, Larrosa-Lombardi, Simon, Barchfeld, Thomas, Cleff, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Short Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857861/
https://www.ncbi.nlm.nih.gov/pubmed/33537898
http://dx.doi.org/10.1007/s00415-021-10428-6
Descripción
Sumario:We report on a patient with refractory Myasthenia gravis with acetylcholine receptor antibodies with two prior myasthenic crises suffering from COVID-19 with rapid evolving weakness and respiratory failure. Respiratory failure developed and prolonged mechanical ventilation was necessary. After plasmapheresis, residual, severe generalized and bulbar weakness persisted. Complement inhibition with eculizumab was, therefore, introduced and lead to rapid recovery. In refractory myasthenic crisis individualised therapies could be successful.

Ejemplares similares